2024 韩国心肌梗塞学会/全国循证医疗合作机构《急性冠状动脉综合征药物治疗指南》。

IF 3 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Hyun Kuk Kim, Seungeun Ryoo, Seung Hun Lee, Doyeon Hwang, Ki Hong Choi, Jungeun Park, Hyeon-Jeong Lee, Chang-Hwan Yoon, Jang Hoon Lee, Joo-Yong Hahn, Young Joon Hong, Jin Yong Hwang, Myung Ho Jeong, Dong Ah Park, Chang-Wook Nam, Weon Kim
{"title":"2024 韩国心肌梗塞学会/全国循证医疗合作机构《急性冠状动脉综合征药物治疗指南》。","authors":"Hyun Kuk Kim, Seungeun Ryoo, Seung Hun Lee, Doyeon Hwang, Ki Hong Choi, Jungeun Park, Hyeon-Jeong Lee, Chang-Hwan Yoon, Jang Hoon Lee, Joo-Yong Hahn, Young Joon Hong, Jin Yong Hwang, Myung Ho Jeong, Dong Ah Park, Chang-Wook Nam, Weon Kim","doi":"10.4070/kcj.2024.0257","DOIUrl":null,"url":null,"abstract":"<p><p>Many countries have published clinical practice guidelines for appropriate clinical decisions, optimal treatment, and improved clinical outcomes in patients with acute coronary syndrome. Developing guidelines that are specifically tailored to the Korean environment is crucial, considering the treatment system, available medications and medical devices, racial differences, and level of language communication. In 2017, the Korean Society of Myocardial Infarction established a guideline development committee. However, at that time, it was not feasible to develop guidelines, owing to the lack of knowledge and experience in guideline development and the absence of methodology experts. In 2022, the National Evidence-Based Healthcare Collaborating Agency collaborated with a relevant academic association to develop internationally reliable guidelines, with strict adherence to the methodology for evidence-based guideline development. The first Korean acute coronary syndrome guideline starts from the 9 key questions for pharmacotherapy.</p>","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"2024 Korean Society of Myocardial Infarction/National Evidence-Based Healthcare Collaborating Agency Guideline for the Pharmacotherapy of Acute Coronary Syndromes.\",\"authors\":\"Hyun Kuk Kim, Seungeun Ryoo, Seung Hun Lee, Doyeon Hwang, Ki Hong Choi, Jungeun Park, Hyeon-Jeong Lee, Chang-Hwan Yoon, Jang Hoon Lee, Joo-Yong Hahn, Young Joon Hong, Jin Yong Hwang, Myung Ho Jeong, Dong Ah Park, Chang-Wook Nam, Weon Kim\",\"doi\":\"10.4070/kcj.2024.0257\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Many countries have published clinical practice guidelines for appropriate clinical decisions, optimal treatment, and improved clinical outcomes in patients with acute coronary syndrome. Developing guidelines that are specifically tailored to the Korean environment is crucial, considering the treatment system, available medications and medical devices, racial differences, and level of language communication. In 2017, the Korean Society of Myocardial Infarction established a guideline development committee. However, at that time, it was not feasible to develop guidelines, owing to the lack of knowledge and experience in guideline development and the absence of methodology experts. In 2022, the National Evidence-Based Healthcare Collaborating Agency collaborated with a relevant academic association to develop internationally reliable guidelines, with strict adherence to the methodology for evidence-based guideline development. The first Korean acute coronary syndrome guideline starts from the 9 key questions for pharmacotherapy.</p>\",\"PeriodicalId\":17850,\"journal\":{\"name\":\"Korean Circulation Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Korean Circulation Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4070/kcj.2024.0257\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Korean Circulation Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4070/kcj.2024.0257","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

许多国家都发布了临床实践指南,以帮助急性冠状动脉综合征患者做出适当的临床决策、进行最佳治疗并改善临床疗效。考虑到治疗系统、可用药物和医疗设备、种族差异以及语言交流水平,制定专门针对韩国环境的指南至关重要。2017 年,韩国心肌梗死学会成立了指南制定委员会。但当时由于缺乏制定指南的知识和经验,也没有方法论专家,因此制定指南并不可行。2022 年,国家循证医疗协作机构与相关学术协会合作,严格遵守循证指南制定方法,制定了国际上可靠的指南。韩国首部急性冠脉综合征指南从药物治疗的 9 个关键问题入手。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
2024 Korean Society of Myocardial Infarction/National Evidence-Based Healthcare Collaborating Agency Guideline for the Pharmacotherapy of Acute Coronary Syndromes.

Many countries have published clinical practice guidelines for appropriate clinical decisions, optimal treatment, and improved clinical outcomes in patients with acute coronary syndrome. Developing guidelines that are specifically tailored to the Korean environment is crucial, considering the treatment system, available medications and medical devices, racial differences, and level of language communication. In 2017, the Korean Society of Myocardial Infarction established a guideline development committee. However, at that time, it was not feasible to develop guidelines, owing to the lack of knowledge and experience in guideline development and the absence of methodology experts. In 2022, the National Evidence-Based Healthcare Collaborating Agency collaborated with a relevant academic association to develop internationally reliable guidelines, with strict adherence to the methodology for evidence-based guideline development. The first Korean acute coronary syndrome guideline starts from the 9 key questions for pharmacotherapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Korean Circulation Journal
Korean Circulation Journal CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
4.90
自引率
17.20%
发文量
103
期刊介绍: Korean Circulation Journal is the official journal of the Korean Society of Cardiology, the Korean Pediatric Heart Society, the Korean Society of Interventional Cardiology, and the Korean Society of Heart Failure. Abbreviated title is ''Korean Circ J''. Korean Circulation Journal, established in 1971, is a professional, peer-reviewed journal covering all aspects of cardiovascular medicine, including original articles of basic research and clinical findings, review articles, editorials, images in cardiovascular medicine, and letters to the editor. Korean Circulation Journal is published monthly in English and publishes scientific and state-of-the-art clinical articles aimed at improving human health in general and contributing to the treatment and prevention of cardiovascular diseases in particular. The journal is published on the official website (https://e-kcj.org). It is indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, Web of Science), Scopus, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, KoreaMed, KoreaMed Synapse and KoMCI, and easily available to wide international researchers
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信